Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Consensus Target Price of $13.86 According to Brokerages

Key Points

• Analysts have a consensus “Hold” rating on Bicycle Therapeutics, with five buys, three holds and one sell among nine analysts. The average 12-month price target is $13.86, compared with the stock’s reported opening price of $3.68.
• Bicycle Therapeutics reported a quarterly loss of $0.72 per share, missing the $0.58 consensus estimate, while revenue of $0.63 million fell well short of the $4.22 million forecast.
• The clinical-stage biotechnology company focuses on oncology medicines using its proprietary constrained-peptide technology; institutional investors own 86.15% of its shares, while insiders have recently sold a limited number of shares.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has received a consensus recommendation of "Hold" from the nine analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $13.86.

BCYC has been the topic of a number of research analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Citigroup reiterated a "market outperform" rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Needham & Company LLC decreased their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $3.68 on Friday. The stock has a market cap of $257.57 million, a P/E ratio of -1.35 and a beta of 1.54. Bicycle Therapeutics has a fifty-two week low of $3.57 and a fifty-two week high of $9.16. The firm's fifty day moving average price is $4.02 and its 200-day moving average price is $4.37.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The business had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Sell-side analysts predict that Bicycle Therapeutics will post -2.26 earnings per share for the current year.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the business's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the transaction, the chief executive officer owned 605,408 shares of the company's stock, valued at $2,585,092.16. The trade was a 0.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 9,977 shares of company stock valued at $42,702. 22.00% of the stock is owned by insiders.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds have recently made changes to their positions in BCYC. Armistice Capital LLC increased its stake in Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company's stock valued at $22,911,000 after acquiring an additional 258,000 shares during the last quarter. Renaissance Technologies LLC raised its position in Bicycle Therapeutics by 72.8% during the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company's stock valued at $4,544,000 after purchasing an additional 412,700 shares in the last quarter. Flax Pond Capital LLC bought a new stake in Bicycle Therapeutics during the fourth quarter worth about $1,229,000. GAMMA Investing LLC lifted its stake in Bicycle Therapeutics by 512.9% during the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company's stock worth $33,000 after purchasing an additional 6,447 shares during the last quarter. Finally, Marquette Asset Management LLC purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $309,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc NASDAQ: BCYC is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines.

The company's research and development activities are focused primarily on oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.